Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-7
2017-002261-22Phase 3Unknown
- Sponsor
- Kite Pharma
- Start
- Dec 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Axicabtagene ciloleucel with Standard of care (2 arms). Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2017-002261-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002261-22.